

Quantom Biosciences Launches Ntensify[™] mano: A Groundbreaking kit for Rapid and Scalable mRNA Production

Nivelles, Belgium – Wednesday, March 13, 2024

Quantom Biosciences S.A. (“Quantom”), a subsidiary of Univercells S.A., proudly announces the extension of the Ntensify[™] product line with the launch of Ntensify[™] mano, an mRNA kit containing reagent mixes for mRNA production and purification in the research context. The all-in-one kit is a cost-effective solution for mRNA production. It combines convenience, efficiency, and control. By providing optimized components for both IVT and downstream purification, Ntensify[™] mano ensures high-quality results while reducing variability and saving time. The mano is based on Quantom's existing technology but eliminates the need to invest in equipment and enables manual small-scale research production of mRNA in less than three hours.

The Ntensify[™] mano kit is based on the highly successful Ntensify[™] process. The effectiveness of the Ntensify[™] process has already been demonstrated in larger-scale production equipment for both clinical trials and commercial production of mRNA globally. This construct-agnostic process integrates an optimized one-pot in vitro transcription with co-transcriptional capping and a redesigned single-step purification to minimize mRNA losses and increase the availability of drug-substance mRNA. The Ntensify[™] process is the result of an advanced Design of Experiments (DoE) and has been continually refined over the past four years.

The Ntensify[™] process has been designed to operate at different scales. Starting with the Ntensify[™] mano kit, scientists can produce mRNA for research purposes without needing any specialized equipment. The same process can be seamlessly scaled up to produce small-scale quantities for pre-clinical application on the Ntensify[™] mini platform. Mid-scale quantities for clinical trials require the Ntensify[™] midi while large-scale commercial production can be carried out on the Ntensify[™] maxi. By designing and using proprietary disposables, this range of equipment removes the need for comparability studies beyond 20mL, facilitating rapid scale-up required in pandemic contexts such as during the last COVID-19 outbreak. Quantom Biosciences remains at the forefront of enabling its partners to achieve cost-effective, low-footprint, high-quality, and low-impurity RNA production.

José Castillo, CEO of Quantom Biosciences and CTO of Univercells, expresses his enthusiasm: “I am thrilled about expanding our product range with the Ntensify mano. It offers an invaluable solution for researchers needing efficient mRNA production on a smaller scale and at speed. I am pleased that they will benefit from our extensive expertise in such a compact kit.

About Quantom Biosciences

Founded in June 2021, Quantom Biosciences emerged after nearly a year of incubation within Univercells, its parent company, whose primary mission is to make biologics available to all. The

project aimed to overcome challenges linked to mRNA-based vaccine and therapeutics production, accentuated by the global impact of the COVID-19 pandemic.

Quantoom Biosciences is reinventing mRNA production by developing an RNA platform including RNA manufacturing and formulation. Our RNA manufacturing technology, NtensifyTM, encompassing process, equipment, reagent mixes, and disposables designed for seamless integration across various scales, is an ideal choice from pre-clinical development to large-scale manufacturing. NcapsulateTM is a fully integrated and automated system tailored for GMP mRNA formulation and designed to meet the rigorous standards of both clinical and commercial manufacturing. Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem. Quantoom Biosciences is part of [Univercells](#), a global life sciences Group with the mission of making biologics accessible to all".

www.quantoom.com

Contact details

Quantoom Biosciences

Jonathan Lecocq

Marketing and Communication Manager

j.lecocq@quantoom.com

Disclosure Statement

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.